Navigation Links
Amgen to Highlight New Data at Upcoming ESC Congress 2013
Date:8/27/2013

lar Outcomes Following Inhibition of PCSK9 In Different POpulations, is a large and comprehensive clinical trial program evaluating AMG 145.7,8

The Phase 3 clinical trial program for AMG 145 builds upon the successful Phase 2 studies and includes 12 trials, with a combined planned enrollment of more than 27,000 patients.3 The Phase 3 studies will evaluate AMG 145 administered every two weeks and monthly in multiple patient populations, including in combination with statins in patients with hyperlipidemia (LAPLACE-2), in patients with hyperlipidemia who cannot tolerate statins (GAUSS-2), as a stand-alone treatment in patients with hyperlipidemia (MENDEL-2), and in patients whose elevated cholesterol is caused by genetic disorders called heterozygous (RUTHERFORD-2) and homozygous (TESLA and TAUSSIG) familial hypercholesterolemia.7

Five studies of AMG 145 will provide long-term safety and efficacy data, including the FOURIER (Further Cardiovascular OUtcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk) study, which will assess whether treatment with AMG 145 compared to placebo reduces recurrent cardiovascular events in approximately 22,500 patients with cardiovascular disease.9-13

Additional information about clinical trials of AMG 145 can be found at www.clinicaltrials.gov.

About Amgen
Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.

Amgen focuses on areas of high unmet medical need and leverages its biologics manufacturing expertise to strive for solut
'/>"/>

SOURCE Amgen
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Acquisition of Onyx Pharmaceuticals, Inc. by Amgen Inc. May Not Be in the Best Interests of Onyx Pharmaceuticals, Inc. Shareholders
2. Amgen To Acquire Onyx Pharmaceuticals For $125 Per Share In Cash
3. Morning Research: BioCryst Pharma Inc., Questcor Pharma Inc., PDL BioPharma Inc., and Amgen Inc.
4. Amgens Second Quarter 2013 Revenues Increased 5 Percent To $4.7 Billion And Adjusted Earnings Per Share (EPS) Increased 3 Percent To $1.89
5. Amgen Announces Webcast of 2013 Second Quarter Financial Results
6. Amgen Award For Science Teaching Excellence Honors Outstanding Teachers
7. Amgen Announces Top-Line Results Of Phase 3 Trebananib (AMG 386) TRINOVA-1 Trial In Recurrent Ovarian Cancer
8. Amgen Presents Positive Results From Talimogene Laherparepvec Phase 3 Study In Patients With Metastatic Melanoma
9. Amgen To Webcast Investor Meeting At Upcoming American Society Of Clinical Oncology Annual Meeting
10. Amgen And Astellas Announce Japan Alliance
11. Amgen to Present at the Deutsche Bank 38th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2015)... May 22, 2015 Research and Markets ... of the "Latest Regulations on Pharmaceutical International ... their offering. This is first time ... guidance on international multi-center clinical trials of drugs ... begun to be implemented on March 1, 2015. ...
(Date:5/22/2015)... , May 22, 2015 AcelRx Pharmaceuticals, ... focused on the development and commercialization of innovative therapies ... announced that interim chief executive officer Howie Rosen ... and chief financial officer Tim Morris will ... of the two presentations are as follows: ...
(Date:5/21/2015)... -- Research and Markets ( http://www.researchandmarkets.com/research/jx648d/north_american ... "North American Active Wound Care Market by Method ... Ulcer), by End-User (In-Patient, & Out-Paient) - Analysis ... offering. ,     (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , ,The North American ... at a CAGR of 3.1% from 2014 to ...
Breaking Medicine Technology:2015 Regulations on Pharmaceutical International Multi-Center Clinical Trials in China 2AcelRx Pharmaceuticals to Present at Two Upcoming Investor Conferences In June 2North American Active Wound Care Market 2015-2019 with Smith and Nephew, Molyncke HealthCare & ConvaTec Dominating 2
... Inc., today announced Phase 2b trial results for its ... levels by 30 to 40 percent in patients whose ... The study included an arm combining DCCR with fenofibrate ... arm, DCCR was shown to be additive to fenofibrate ...
... iBio, Inc. (NYSE AMEX: IBIO) today announced ... iBio,s proprietary fusion-protein technology in combination with influenza virus ... use of lichenase in an adjuvant-like role to improve ... the Fraunhofer USA Center for Molecular Biotechnology (FhCMB), iBio,s ...
Cached Medicine Technology:Phase 2b Trial Shows Unique Lipid Efficacy Profile of Novel Compound to Reduce Elevated Triglyceride Levels 2Phase 2b Trial Shows Unique Lipid Efficacy Profile of Novel Compound to Reduce Elevated Triglyceride Levels 3Patent Issued on Fusion-Protein Vaccine Technology 2Patent Issued on Fusion-Protein Vaccine Technology 3
(Date:5/26/2015)... Dearborn Ear, Nose & Throat in Dearborn, ... new and improved website to better showcase their Detroit ... Ear, Nose & Throat’s new website utilizes an innovative ... website seamlessly on any desktop computer, tablet or mobile ... Ear, Nose & Throat website include an innovative ...
(Date:5/25/2015)... May 26, 2015 The report ... comprehensive information on the therapeutic development for Liver ... new targets and MOAs to produce first-in-class and ... review of Liver Failure with 22 market data ... is available at http://www.rnrmarketresearch.com/liver-failure-pipeline-review-h1-2015-market-report.html . , ...
(Date:5/25/2015)... Author Vincent N. Cefalu, Sr., MD. has always believed ... many of them aren’t aware of many products that are ... don’t realize the dangers of physical inactivity and the many ... that exist. There is also the fact that smokers ... , In “ A Doctor’s Prescription for Longevity and Survival ...
(Date:5/25/2015)... 2015 The National Association of ... 2015-2016 inductee into its VIP Professional Woman of the ... for leadership in dentistry. NAPW is the nation's leading ... 700,000 members and over 200 operating local chapters. ... group of professional women,” said NAPW President Star Jones. ...
(Date:5/25/2015)... 2015 The National Association of ... as a 2015-2016 inductee into its VIP Woman ... prestigious distinction for leadership in biomedical engineering. NAPW is ... boasting more than 700,000 members and over 200 operating ... this exceptional group of professional women," said NAPW President ...
Breaking Medicine News(10 mins):Health News:Dearborn Ear, Nose & Throat Launches ‘Responsive Design’ Website 2Health News:Liver Failure Pipeline Assessment and Key Players Review H1 2015 Market Research Report Available at RnRMarketResearch.com 2Health News:Liver Failure Pipeline Assessment and Key Players Review H1 2015 Market Research Report Available at RnRMarketResearch.com 3Health News:Liver Failure Pipeline Assessment and Key Players Review H1 2015 Market Research Report Available at RnRMarketResearch.com 4Health News:New Book Reveals ‘A Doctor’s Prescription for Longevity and Survival’ 2Health News:New Book Reveals ‘A Doctor’s Prescription for Longevity and Survival’ 3Health News:National Association of Professional Women Inducts Dr. Laquinas Hooked, D.D.S. of General Dentist, Into its VIP Professional Woman of the Year Circle 2Health News:National Association of Professional Women Inducts Lisa Ferrara, Ph.D., CEO of OrthoKinetic Technologies, Into its VIP Professional Woman of the Year Circle 2
... genetic mutation that improves response to therapy , , WEDNESDAY, ... inhibits tumor blood vessel formation slows the progression of ... finds. , Of the 93 patients with rapidly progressing ... motesanib diphosphate. Of those 49 patients, 14 percent had ...
... Compact, bedside brain-activity monitors detected most seizures in ... Medicine in St. Louis showed. That means the ... electrical seizures until confirmation with conventional EEG (electroencephalography), ... the June issue of Pediatrics . ...
... CEO, American Association of,Homes and Services for the ... Exceptions Process, WASHINGTON, July 2 Following ... American Association of Homes and,Services for the Aging, ... Process:, "Medicare beneficiaries are once again having ...
... that its President and Chief Executive Officer Sean ... Year(R) 2008 Award in the,Applied Science category in ... region. This award recognizes outstanding entrepreneurs who,are building ... an independent panel of judges and the award ...
... (THURSDAY) 10:00 A.M., WASHINGTON, July 2 Food ... regulation that would require,growers and packers of fruits and ... those products to be traced back to their farm,of ... will reiterate its,call for growers to implement written food ...
... David Belkin died,last February during a pick-up basketball game, but ... tell about it., On Sunday, July 6 at 11 ... with the Sudden Cardiac Arrest (SCA) Foundation,s,People Saving People Award ... Rd. (behind Wayne Memorial Hospital) in Honesdale., Also invited ...
Cached Medicine News:Health News:New Drug Slows Thyroid Cancer 2Health News:Seizures in newborns can be detected with small, portable brain activity monitors 2Health News:Seizures in newborns can be detected with small, portable brain activity monitors 3Health News:AAHSA Statement: Therapy Caps Ration Care 2Health News:Precision Therapeutics President and CEO Sean McDonald Named Ernst & Young Entrepreneur of the Year(R) 2008 Regional Award Winner 2Health News:Back From the Dead: Cardiac Arrest Victim Salutes His Rescuer 2
... grafting or creation of a vascular access, ... is of the utmost importance in many ... for those seeking a high-precision tunneling instrument. ... risk of twisting or kinking for more ...
... Cardiovascular Patch utilizes advanced fluoropolymer ... around penetrating suture and decrease ... much as 88 percent. This ... retention, multi-directional strength and low ...
... have met the challenges of the ... exceptional performance and quality, they have ... worldwide. These grafts require no preclotting, ... infection, and ensure utmost thrombectomy safety. ...
... GORE-TEX Stretch Vascular Grafts have met ... vascular procedures. Recognized for exceptional performance ... endorsement of renowned surgeons worldwide. These ... and the spread of infection, and ...
Medicine Products: